C

에이비프로바이오

195990KOSDAQ특수 목적용 기계 제조업

41.7 / 100

Reference Date: 2026-04-13

Financial Score14.0 / 40
News Sentiment9.7 / 25
Momentum4.0 / 20
Disclosure14.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly down 2.8% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

AB ProBio operates three core business segments: a machine tool division specializing in small machining centers (UT and MAX series), a biopharmaceutical development division that acquired rights to develop dual-antibody drugs targeting HER2 and VEGF from Abpro Corporation, and a semiconductor equipment division expanded through the acquisition of ANAH in 2023. The company produces high-performance machining centers tailored for IT and electronics manufacturing, while advancing biopharmaceutical R&D in Asia, CIS countries, and the Middle East.

Number of Employees

43people

Average Salary

0.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 22.894.0Point
PBR
0.73Industry Average 1.557.0Point

Half of industry avg (excellent)

ROE
-60.38Industry Average 1.250.0Point

Well below industry avg

Debt Ratio
22.87Industry Average 7.700.0Point

3.0x industry avg (risky)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲12.8% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼3.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -31.2% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 0Neutral 0Negative 3Average Sentiment Score 35

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 1,390Won52-week high 3,38252-week low 1,100
1-month return2.0Point

1m -2.80% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

25 totalPositive 2Neutral 23Negative 0
  • Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-04-10
  • Neutral주주총회소집결의 (임시주주총회)2026-04-10
  • Neutral주주명부폐쇄기간또는기준일설정2026-04-10
  • Neutral주식등의대량보유상황보고서(일반)2026-04-08
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-08